In the very small 1-year study reported at the link below, Lucentis and Avastin had a similar therapuetic benefit, but Lucentis required fewer injections. I recall that when Lucentis was approved, Genentech touted the shorter half life of Lucentis as an advantage Lucentis held over Avastin. You would think, however, that a shorter half life would mean more, rather than fewer, injections. The link gives some possible explanations for this result. The NEI trial data should be interesting.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.